NASDAQ:FWBI • US33749P4081
The current stock price of FWBI is 2.96 USD. Today FWBI is up by 4.59%. In the past month the price increased by 4.23%. In the past year, price decreased by -93.21%.
ChartMill assigns a technical rating of 1 / 10 to FWBI. When comparing the yearly performance of all stocks, FWBI is a bad performer in the overall market: 98.3% of all stocks are doing better.
ChartMill assigns a fundamental rating of 1 / 10 to FWBI. FWBI may be in some trouble as it scores bad on both profitability and health.
8 analysts have analysed FWBI and the average price target is 36.72 USD. This implies a price increase of 1140.54% is expected in the next year compared to the current price of 2.96.
Over the last trailing twelve months FWBI reported a non-GAAP Earnings per Share(EPS) of -88.75. The EPS increased by 75.5% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -233.87% | ||
| ROE | -446.8% | ||
| Debt/Equity | 0.17 |
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.3 | 402.17B | ||
| AMGN | AMGEN INC | 16.45 | 203.213B | ||
| GILD | GILEAD SCIENCES INC | 16.81 | 182.029B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.75 | 117.075B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.51 | 82.631B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 43.21 | 42.915B | ||
| INSM | INSMED INC | N/A | 30.852B | ||
| NTRA | NATERA INC | N/A | 29.086B | ||
| BIIB | BIOGEN INC | 11.72 | 27.626B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.94 | 23.193B | ||
| MRNA | MODERNA INC | N/A | 22.014B | ||
| EXAS | EXACT SCIENCES CORP | 340.08 | 19.797B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.775B |
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
First Wave BioPharma Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Boca Raton, Florida and currently employs 10 full-time employees. The company went IPO on 2016-10-11. First Wave BioPharma, Inc. is a clinical-stage biopharmaceutical company. The firm is engaged in the research and development of targeted, non-systemic therapies for the treatment of patients with gastrointestinal (GI) diseases. The company is focused on developing its pipeline of gut-restricted GI clinical drug candidates, including the biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients, and niclosamide, which is an oral small molecule with anti-viral and anti-inflammatory properties. Its adrulipase programs are focused on the development of an oral, non-systemic, biologic capsule for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis and chronic pancreatitis. The company is advancing two separate Phase 2 clinical programs of its niclosamide formulations, including FW-COV for Severe Acute Respiratory Syndrome Coronavirus 2 GI infections, and FW-UP for ulcerative proctitis and ulcerative proctosigmoiditis.
IPO: 2016-10-11
FIRST WAVE BIOPHARMA
777 Yamato Road, Suite 502
Boca Raton FLORIDA US
CEO: James Sapirstein
Employees: 10
Phone: 15615897020
First Wave BioPharma Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Boca Raton, Florida and currently employs 10 full-time employees. The company went IPO on 2016-10-11. First Wave BioPharma, Inc. is a clinical-stage biopharmaceutical company. The firm is engaged in the research and development of targeted, non-systemic therapies for the treatment of patients with gastrointestinal (GI) diseases. The company is focused on developing its pipeline of gut-restricted GI clinical drug candidates, including the biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients, and niclosamide, which is an oral small molecule with anti-viral and anti-inflammatory properties. Its adrulipase programs are focused on the development of an oral, non-systemic, biologic capsule for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis and chronic pancreatitis. The company is advancing two separate Phase 2 clinical programs of its niclosamide formulations, including FW-COV for Severe Acute Respiratory Syndrome Coronavirus 2 GI infections, and FW-UP for ulcerative proctitis and ulcerative proctosigmoiditis.
The current stock price of FWBI is 2.96 USD. The price increased by 4.59% in the last trading session.
FWBI does not pay a dividend.
FWBI has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
FIRST WAVE BIOPHARMA (FWBI) operates in the Health Care sector and the Biotechnology industry.
FIRST WAVE BIOPHARMA (FWBI) has a market capitalization of 4.62M USD. This makes FWBI a Nano Cap stock.